



## **STATEMENT**

### **Faes Farma licences Bilastine's marketing rights to Nycomed in Brazil.**

Faes Farma and the European multinational Nycomed have signed a licence agreement for the commercialization of Bilastine in Brazil.

With this agreement, Bilastine will be commercialized in the Brazilian market by one of the ten biggest companies in Brazil, with a very important presence in the respiratory area.

Brazil is a great emerging market that represents the biggest market in Latin America and the world's tenth, with a rapid growth rate (13% approximately during 2009).

The signing of this agreement complements the ones signed in other big emerging markets, where growth rates of 13-16% are predicted for the next five years. So far, in these markets, Faes Farma has signed agreements in Mexico with the world's number one Pfizer, in India with the third local company, Merck Serono, in Russia with the important Berlin Chemie/Menarini, in South Korea with the local leader Yuhan Corporation and in Turkey with Menarini and probably, with another multinational. Meanwhile, negotiations continue with possible candidates in order to choose the best partner in China.

December 28<sup>th</sup>, 2009.